{"title":"关于由 TAS2R38 基因型介导的味觉多态性的荟萃分析。","authors":"Vishnu Shivam","doi":"10.1037/pha0000728","DOIUrl":null,"url":null,"abstract":"<p><p>The objective of this study is to review the association of TAS2R38 polymorphisms and taste phenotypes to bitter compounds (phenylthiocarbamide [PTC]/propylthiouracil [PROP]), and its association among persons who drink alcohol and individuals with smoking behavior. A literature search was carried out in PubMed, ScienceDirect, Cochrane, and Wiley online library databases using the keyword \"(Bitter taste receptor genes OR TAS2R38) AND (PROP OR propylthiouracil) AND (PTC OR phenylthiocarbamide),\" \"(Bitter taste receptor genes OR TAS2R38) AND (alcohol),\" \"(Bitter taste receptor genes OR TAS2R38) AND (tobacco OR smoker)\" to find articles evaluating the association of taste phenotypes and TAS2R38 polymorphisms, and its association among persons who drink alcohol and individuals with smoking behavior. The analysis show that TAS2R38 taster genotype (proline-alanine-valine [PAV] allele) was significantly (OR, 5.88; CI [3.87, 8.95], <i>p</i> < .001) associated with taster phenotype for bitter compounds (PTC/PROP), and TAS2R38 nontaster genotype (alanine-valine-isoleucine allele) was significantly (OR, 6.73; CI [4.57, 9.90], <i>p</i> < .001) associated with nontaster phenotype for bitter compounds. Further, TAS2R38 taster genotypes (PAV homozygotes and heterozygotes) were significantly associated with higher alcohol intake (OR, 5.15; 95% CI [2.66, 9.98]; <i>p</i> < .001) and among individuals with smoking behavior (OR, 1.73; 95% CI [1.24, 2.42]; <i>p</i> = .001). This suggests that TAS2R38 single nucleotide polymorphisms can be identified by clinically assessing taste phenotype status for bitter compounds and can be used as a potential therapeutic target in the prevention and treatment of harmful higher alcohol intake and smoking behavior. (PsycInfo Database Record (c) 2024 APA, all rights reserved).</p>","PeriodicalId":12089,"journal":{"name":"Experimental and clinical psychopharmacology","volume":null,"pages":null},"PeriodicalIF":2.4000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A meta-analysis on polymorphic trait of taste perception mediated by TAS2R38 genotype.\",\"authors\":\"Vishnu Shivam\",\"doi\":\"10.1037/pha0000728\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The objective of this study is to review the association of TAS2R38 polymorphisms and taste phenotypes to bitter compounds (phenylthiocarbamide [PTC]/propylthiouracil [PROP]), and its association among persons who drink alcohol and individuals with smoking behavior. A literature search was carried out in PubMed, ScienceDirect, Cochrane, and Wiley online library databases using the keyword \\\"(Bitter taste receptor genes OR TAS2R38) AND (PROP OR propylthiouracil) AND (PTC OR phenylthiocarbamide),\\\" \\\"(Bitter taste receptor genes OR TAS2R38) AND (alcohol),\\\" \\\"(Bitter taste receptor genes OR TAS2R38) AND (tobacco OR smoker)\\\" to find articles evaluating the association of taste phenotypes and TAS2R38 polymorphisms, and its association among persons who drink alcohol and individuals with smoking behavior. The analysis show that TAS2R38 taster genotype (proline-alanine-valine [PAV] allele) was significantly (OR, 5.88; CI [3.87, 8.95], <i>p</i> < .001) associated with taster phenotype for bitter compounds (PTC/PROP), and TAS2R38 nontaster genotype (alanine-valine-isoleucine allele) was significantly (OR, 6.73; CI [4.57, 9.90], <i>p</i> < .001) associated with nontaster phenotype for bitter compounds. Further, TAS2R38 taster genotypes (PAV homozygotes and heterozygotes) were significantly associated with higher alcohol intake (OR, 5.15; 95% CI [2.66, 9.98]; <i>p</i> < .001) and among individuals with smoking behavior (OR, 1.73; 95% CI [1.24, 2.42]; <i>p</i> = .001). This suggests that TAS2R38 single nucleotide polymorphisms can be identified by clinically assessing taste phenotype status for bitter compounds and can be used as a potential therapeutic target in the prevention and treatment of harmful higher alcohol intake and smoking behavior. (PsycInfo Database Record (c) 2024 APA, all rights reserved).</p>\",\"PeriodicalId\":12089,\"journal\":{\"name\":\"Experimental and clinical psychopharmacology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Experimental and clinical psychopharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1037/pha0000728\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/5/30 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental and clinical psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1037/pha0000728","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/30 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
摘要
本研究旨在回顾 TAS2R38 多态性与苦味化合物(苯硫基甲酰胺 [PTC] / 丙基硫脲嘧啶 [PROP])味觉表型的相关性,及其与饮酒者和有吸烟行为者的相关性。在 PubMed、ScienceDirect、Cochrane 和 Wiley 在线图书馆数据库中使用关键词"(苦味受体基因或 TAS2R38)和(PROP 或丙基硫脲嘧啶)和(PTC 或苯硫代甲酰胺)"、"(苦味受体基因或 TAS2R38)和(酒精)"进行了文献检索、"(苦味受体基因或 TAS2R38)与(烟草或吸烟者)",以查找评估味觉表型与 TAS2R38 多态性之间关系的文章,及其与饮酒者和有吸烟行为者之间关系的文章。分析表明,TAS2R38 味觉基因型(脯氨酸-丙氨酸-缬氨酸 [PAV] 等位基因)与味觉表型显著相关(OR, 5.88; CI [3.87, 8.95], p < .001)与苦味化合物的品尝表型(PTC/PROP)相关,而 TAS2R38 非品尝基因型(丙氨酸-缬氨酸-异亮氨酸等位基因)与苦味化合物的非品尝表型显著相关(OR,6.73;CI [4.57,9.90],p < .001)。此外,TAS2R38品尝基因型(PAV同源染色体和杂合染色体)与较高的酒精摄入量(OR,5.15;95% CI [2.66,9.98];p < .001)和吸烟行为(OR,1.73;95% CI [1.24,2.42];p = .001)显著相关。这表明,TAS2R38单核苷酸多态性可通过临床评估苦味化合物的味觉表型状态来确定,并可作为预防和治疗有害的高酒精摄入量和吸烟行为的潜在治疗靶点。(PsycInfo Database Record (c) 2024 APA, 版权所有)。
A meta-analysis on polymorphic trait of taste perception mediated by TAS2R38 genotype.
The objective of this study is to review the association of TAS2R38 polymorphisms and taste phenotypes to bitter compounds (phenylthiocarbamide [PTC]/propylthiouracil [PROP]), and its association among persons who drink alcohol and individuals with smoking behavior. A literature search was carried out in PubMed, ScienceDirect, Cochrane, and Wiley online library databases using the keyword "(Bitter taste receptor genes OR TAS2R38) AND (PROP OR propylthiouracil) AND (PTC OR phenylthiocarbamide)," "(Bitter taste receptor genes OR TAS2R38) AND (alcohol)," "(Bitter taste receptor genes OR TAS2R38) AND (tobacco OR smoker)" to find articles evaluating the association of taste phenotypes and TAS2R38 polymorphisms, and its association among persons who drink alcohol and individuals with smoking behavior. The analysis show that TAS2R38 taster genotype (proline-alanine-valine [PAV] allele) was significantly (OR, 5.88; CI [3.87, 8.95], p < .001) associated with taster phenotype for bitter compounds (PTC/PROP), and TAS2R38 nontaster genotype (alanine-valine-isoleucine allele) was significantly (OR, 6.73; CI [4.57, 9.90], p < .001) associated with nontaster phenotype for bitter compounds. Further, TAS2R38 taster genotypes (PAV homozygotes and heterozygotes) were significantly associated with higher alcohol intake (OR, 5.15; 95% CI [2.66, 9.98]; p < .001) and among individuals with smoking behavior (OR, 1.73; 95% CI [1.24, 2.42]; p = .001). This suggests that TAS2R38 single nucleotide polymorphisms can be identified by clinically assessing taste phenotype status for bitter compounds and can be used as a potential therapeutic target in the prevention and treatment of harmful higher alcohol intake and smoking behavior. (PsycInfo Database Record (c) 2024 APA, all rights reserved).
期刊介绍:
Experimental and Clinical Psychopharmacology publishes advances in translational and interdisciplinary research on psychopharmacology, broadly defined, and/or substance abuse.